A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia
T Fukushima, Y Urasaki, M Yamaguchi… - Anticancer …, 2012 - ar.iiarjournals.org
Background: We conducted a prospective, multicenter cooperative study to compare two
courses of modified intermediate-dose cytarabine (Ara-C)(mIDAC; Ara-C at a dose of 1.0 …
courses of modified intermediate-dose cytarabine (Ara-C)(mIDAC; Ara-C at a dose of 1.0 …
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia: Southwest …
C Karanes, KJ Kopecky, DR Head, MR Grever… - Leukemia research, 1999 - Elsevier
The aim of this study is to determine whether the addition of mitoxantrone to high dose
cytarabine improves the outcome of treatment in patients with relapsed or refractory acute …
cytarabine improves the outcome of treatment in patients with relapsed or refractory acute …
A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid …
RM Stone, SL Allen, A Pigneux, RK Stuart… - Journal of Clinical …, 2011 - ascopubs.org
6520 Background: Secondary acute myeloid leukemia (sAML; after antecedent histologically
documented myelodysplastic syndrome or arising from prior chemo or radiation therapy for …
documented myelodysplastic syndrome or arising from prior chemo or radiation therapy for …
Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukemia
H Wei, Y Wang, RP Gale, D Lin, C Zhou, B Liu… - Clinical Cancer …, 2020 - AACR
Abstract Purpose: Cytarabine, 100–200 mg/mE+ 2/day, is commonly used in induction
therapy of acute myelogenous leukemia (AML). Whether a higher dose of cytarabine would …
therapy of acute myelogenous leukemia (AML). Whether a higher dose of cytarabine would …
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a …
JK Weick, KJ Kopecky, FR Appelbaum, DR Head… - 1996 - ashpublications.org
Interest in high-dose cytarabine (HDAC) for both induction and postremission therapy for
acute myeloid leukemia (AML) prompted the Southwest Oncology Group (SWOG) to initiate …
acute myeloid leukemia (AML) prompted the Southwest Oncology Group (SWOG) to initiate …
Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group …
C Robles, KM Kim, MM Oken, JM Bennett, L Letendre… - Leukemia, 2000 - nature.com
Abstract The Eastern Cooperative Oncology Group (ECOG) conducted a prospective phase
III study in patients with relapsed/refractory acute myeloid leukemia (AML) to evaluate …
III study in patients with relapsed/refractory acute myeloid leukemia (AML) to evaluate …
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia
HM Ghaddar, S Pierce, HM Kantarjian… - Leukemia & …, 1996 - Taylor & Francis
The overall cure rate of adults with newly-diagnosed acute myelogenous leukemia (AML)
treated with continuous infusion high-dose cytarabine (CIHDAC) is comparable to that with …
treated with continuous infusion high-dose cytarabine (CIHDAC) is comparable to that with …
Comparison of three doses of cytarabine consolidation for intermediate-and adverse-risk acute myeloid leukemia: real world evidence from Thai acute myeloid …
C Chanswangphuwana, C Polprasert… - … Myeloma and Leukemia, 2022 - Elsevier
Background Intermediate or high doses of cytarabine (IDAC or HiDAC) were recommended
as postremission chemotherapy for acute myeloid leukemia (AML). This retrospective study …
as postremission chemotherapy for acute myeloid leukemia (AML). This retrospective study …
Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia
Objective: The current trial attempted to evaluate the efficacy and toxicity of a salvage
therapy consisting of amsacrine plus intermediate-dose Ara-C (IDAC) with or without …
therapy consisting of amsacrine plus intermediate-dose Ara-C (IDAC) with or without …
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute …
S Miyawaki, S Ohtake, S Fujisawa… - Blood, The Journal …, 2011 - ashpublications.org
We conducted a prospective randomized study to assess the optimal postremission therapy
for adult acute myeloid leukemia in patients younger than 65 years in the first complete …
for adult acute myeloid leukemia in patients younger than 65 years in the first complete …